Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib
Authors
Keywords
-
Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-11-07
DOI
10.1111/jgh.14535
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of molecular enrichment on future therapies in hepatocellular carcinoma
- (2018) Jean-Charles Nault et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Systemic Therapy for Hepatocellular Carcinoma: 2017 Update
- (2017) Masatoshi Kudo ONCOLOGY
- Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
- (2016) Zeynep Firtina Karagonlar et al. CANCER SCIENCE
- Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53
- (2016) Wen-Ting Liu et al. CELL CYCLE
- International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007
- (2016) Jessica L. Petrick et al. INTERNATIONAL JOURNAL OF CANCER
- Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
- (2015) Yu-Yun Shao WORLD JOURNAL OF GASTROENTEROLOGY
- Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma
- (2013) K Miyahara et al. BRITISH JOURNAL OF CANCER
- Angiotensin II Induces Angiogenic Factors Production Partly Via AT1/JAK2/STAT3/SOCS3 Signaling Pathway in MHCC97H Cells
- (2013) Yuanyuan Ji et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
- (2013) L. Goyal et al. CLINICAL CANCER RESEARCH
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Evaluation of the mRECIST and a-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
- (2012) Tomokazu Kawaoka et al. ONCOLOGY
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started